We have aimed to summarize recent data on three leading AD treatment strategies including a newly FDA approved anti-amyloid β antibody (Aducanumab)), an anti-tau antibody (Zagotenemab) and a nuclear Peroxisome-Proliferator Activated Receptor γ (PPARγ) agonist (Pioglitazone) from pre-clinical to clinical studies (www.clinicaltrials.gov, accessed November 22, 2020; Table 1). Here, PPARG is linked to Alzheimer disease.